Prospective, multicentre, open-label clinical trial on the effect of GUSelkumab on the resolution of ultrasound-proven ENThEsitis in patients with pSoriatic arthriTis

Prior treatment

• Concomitant florid active immune mediated disease (e.g. autoimmune hepatitis) that is untreated and/or requires immunosuppressive treatment
• History or evidence of ongoing alcohol or drug abuse, within the last six months prior to enrolment
• Use of any inadmissible medication (e.g. drugs under development or bDMARDs approved for PsA other than Guselkumab) List of admitted drugs alongside IMP: • csDMARD - Leflunomide (e.g. Arava), Sulfasalazine (e.g. Azulfidine RA, Pleon RA), Methotrexate (e.g. Lantarel, Metex) and/or • systemic glucocorticoids with a stable dose of ≤ 7,5 mg of prednisolone equivalents within the last 12 weeks of screening

Other illness

• Diagnosis of any other rheumatological/ immunological disease such as rheumatoid arthritis, SLE, PSS, MCTD, Behcet syndrome or GPA
• History of ongoing, chronic or recurrent infectious disease (Infection with HIV, HBV or HCV) or evidence of tuberculosis infection as defined by a positive QuantiFERON Tb-Gold test. If presence of latent tuberculosis is established then treatment according to local country guidelines must have been initiated but patient cannot take part in the study
• History of lymphoproliferative disease or any known malignancy or history of malignancy of any organ system (except for basal cell carcinoma or actinic keratosis that have been treated with no evidence of recurrence in the past 3 months, carcinoma in situ of the cervix or non-invasive malignant colon polyps that have been removed), treated or untreated within the past 5 years prior to enrolment

Other

• Contraindication for Guselkumab treatment according to their SmPCs
• Nursing mother or pregnant woman

• Written informed consent obtained from the subject
• Adult male or female subject; age ≥ 18 years
• Diagnosis of PsA according to CASPAR criteria
• SPARCC Enthesitis ≥ 1 at baseline
• bDMARD naïve or previous treatment with no more than one TNFi
• Failure or adverse reaction to at least one csDMARD or indication to start systemic therapy with Guselkumab due to moderate-to-severe plaques psoriasis
• PD Grade ≥ 2 for at least 1 affected enthesis at baseline or PD Grade ≥ 1 for at least 2 affected entheses at baseline